FDA Confirms Prasugrel Advisory Committee Review; What Will Panel Membership Entail?
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly/Daiichi’s platelet inhibitor prasugrel will be subject of Feb. 3 advisory committee; outcome could hinge on makeup of expert panel.